Serendipity Impact VC
Venture capitalActively deployingNew York · Seed–Series B · 5 people tracked
Investment thesis
The firm invests in breakthrough technologies addressing mental and neurological health challenges, which represent 15% of global disease burden and are projected to cost $6 trillion annually by 2030. The fund partners early with founders to transform scientific innovation into scalable, market-ready solutions through hands-on mentorship, regulatory expertise, and access to Israeli and U.S. innovation networks. The investment thesis emphasizes that solving mental and neuro health challenges will drive the next leap in human progress across healthcare, well-being, and how people live.
Source: firm website, verified Jul 21, 2026.
Team · 5 people
from the firm's websiteNeurotech pioneer and serial entrepreneur with 30+ years in healthcare ventures. Founded and scaled Visionsense, a 3D surgical visualization company, which was acquired by Medtronic for $75M. Co-founder at HealthYA Ventures and former CEO of Joy Ventures. Former Lieutenant in Israel's elite Unit 8200.
Behavioral scientist and venture strategist with 15+ years in U.S. go-to-market strategy for early-stage mental health innovation. Founding Director of the YU Innovation Lab, which supported Israeli and U.S. startups. Strategic advisor to multiple mental health ventures and recognized thought leader translating neuroscience into market-ready solutions.
Marketing strategist and brand builder specializing in digital strategy and founder support. Founder & CEO of TOBO.CREATIVE advising startups on brand positioning and go-to-market planning. Previously led marketing at the YU Innovation Lab supporting 70+ international startups, and launched the first university chapter for emerging music industry talent at Grammy U.
Commercial strategist with 25+ years scaling surgical technologies and healthcare markets. Led commercial operations at Visionsense through its acquisition by Medtronic. Founding Partner at Med-Connect360 advising medtech startups in robotics and AI-powered surgery. Previously held senior roles at Johnson & Johnson launching surgical businesses.
Frequently asked questions
- What stage does Serendipity Impact VC invest at?
- Serendipity Impact VC invests at the Seed, Series A, Series B stages.
- What sectors does Serendipity Impact VC focus on?
- Serendipity Impact VC focuses on Biotech, Healthtech, Medical Devices, Mental Health.
- Where is Serendipity Impact VC located?
- Serendipity Impact VC is headquartered in New York, US.
Similar investors
Think Health is a venture capital firm investing in early-stage and growth healthcare companies with typical check sizes ranging from €500k to €10 million. The firm combines healthcare industry expertise with investment know-how to actively support portfolio companies.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.